Ameriprise Financial Inc Zentalis Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $719,930 - $1.04 Million	-36,675 Reduced 18.1%	166,004 $3.33 Million
Q2 2023 Aug 14, 2023	SELL	$17.41 - $30.05 $1.13 Million - $1.94 Million	-64,626 Reduced 24.18%	202,679 $5.72 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $780,223 - $1.21 Million	48,341 Added 22.08%	267,305 $4.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $623,686 - $883,584	34,515 Added 18.71%	218,964 $4.41 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $220,608 - $346,015	10,905 Added 6.28%	184,449 $3.99 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $3.11 Million - $9.07 Million	173,544 New	173,544 $4.88 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.